Tag:

actavis

Latest Headlines

Latest Headlines

Actavis wins FDA approval for a new 'superbug' antibiotic

Actavis won the FDA's blessing for a new combination antibiotic treatment targeting drug-resistant infections, setting the stage for a showdown with Merck and its $9.5 billion splash into the field.

Actavis has an eye on more deals, for 'couple billion dollars' or so

Actavis, still awaiting the close of its $66 billion buyout of Allergan, is on the lookout for more bolt-on acquisitions.

Can Actavis deliver a promised $6B boost from this pipeline?

The big series of acquisitions that is making Actavis--now changing its name to Allergan--into a top 10 Big Pharma company overnight also bequeathed the company with an oddly disjointed pipeline of would-be blockbusters. And the company rolled it all up for public viewing today for its investors, touting its potential for spurring $6 billion in new sales.

Actavis and the future of discovery-averse 'growth pharma'

Brent Saunders, Actavis chief executive and architect of four major pharma deals, doesn't hate drug discovery. He just doesn't want his company to do it.

Actavis, Richter tout new PhIII data for their tarnished schizophrenia drug

Fourteen months after the FDA rejected the new antipsychotic cariprazine, the developers say they have gathered together a new batch of late-stage data to demonstrate its effectiveness for schizophrenia, but the statement has done little to dispel the lingering doubts about this one-time blockbuster hopeful.

Actavis CEO: We may be big, but we don't want to be Big Pharma

Big Pharma or "growth pharma"? Actavis CEO Brent Saunders is aiming for the latter. Though his company is expected to rank among the industry's top 10 after closing its Allergan buy later this year, Saunders says Actavis won't act like a Big Pharma. What's the difference? He has some ideas.

Actavis revs up new commercial team for post-Allergan-merger sales race

Before Actavis swooped in to grab Allergan from hostile suitor Valeant, analysts said a tie-up between the two could create a marketing superpower. Now, a month after Actavis and Allergan announced their merger agreement, the drugmakers have a plan they think can make that happen.

Marketing lesson from Actavis' Namenda ruling: For a hard switch, keep your mouths shut

Last week, a New York judge called a halt on Actavis' plan to pull Namenda off the market, throwing off its strategy for switching patients to a newer extended-release version. On Monday, the judge nixed Actavis' attempt to block the injunction.

UPDATED: Actavis bags top 10 Big Pharma status with $66B Allergan buyout

Actavis and Allergan have come to terms on a buyout that values the Botox maker at $66 billion, dwarfing a bid from Valeant and William Ackman that forced the biotech into play. And it gives Actavis CEO Brent Saunders exactly what he's been looking for: Bragging rights to top 10 status in the Big Pharma world--after brushing aside a weakening Eli Lilly.

Actavis bid looms as Allergan says it's been approached (again) on merger

Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry Valeant. And the business news outlets quickly identified Actavis as the interested party.